The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions

Cancer and Metastasis Reviews

Volumn 25, Issue 3, 2006, Pages 387-408

  Apte, Ron N ^a   Dotan, Shahar ^a   Elkabets, Moshe ^a   White, Malka R ^a   Reich, Eli ^a   Carmi, Yaron ^a   Song, Xiaping ^a   Dvozkin, Tatyana ^a   Krelin, Yakov ^a   Voronov, Elena ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anti tumor immunity; Carcinogenesis; IL 1 ; IL 1 ; Immunogenicity; Tumor invasiveness; Tumor host interactions

Indexed keywords

ALGINIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; MICROSPHERE; POLYLYSINE; RECOMBINANT INTERLEUKIN 1BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTOMA; ASTROCYTOMA CELL; CANCER; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROSARCOMA; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INFLAMMATION; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH TUMOR; TUMOR CELL; TUMOR IMMUNOLOGY;

AUTOCRINE COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PARACRINE COMMUNICATION;

EID: 33845546703     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-006-9004-4     Document Type: Review

References (165)

1. Nathan, C. (2002). Points of control in inflammation. Nature, 420, 846-852.
2. Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell, 118, 671-674.
3. Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
4. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860-867.
5. Coussens, L. M., & Werb, Z. (2001). Inflammatory cells and cancer: think different! Journal of Experimental Medicine, 193, F23-F26.
6. Cordon-Cardo, C., & Prives, C. (1999). At the crossroads of inflammation and tumorigenesis. Journal of Experimental Medicine, 190, 1367-1370.
7. Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211-217.
8. Philip, M., Rowley, D. A., & Schreiber, H. (2004). Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology, 14, 433-439.
9. Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews, Cancer, 4, 71-78.
10. Vakkila, J., & Lotze, M. T. (2004). Inflammation and necrosis promote tumour growth. Nature Reviews, Immunology, 4, 641-648.
11. Dinarello, C. A., & Moldawer, L. L. (2002). Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primer for clinicians, Third edition. Thousand Oaks, CA: Amgen, pp. 21-51.
12. Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood, 87, 2095-2147.
13. Auron, P. E. (1998). The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine & Growth Factor Reviews, 9, 221-237.
14. Martin, M. U., & Falk, W. (1997). The interleukin-1 receptor complex and interleukin-1 signal transduction. European Cytokine Network, 8, 5-17.
15. Stylianou, E., & Saklatvala, J. (1998). Interleukin-1. International Journal of Biochemistry & Cell Biology, 30, 1075-1079.
16. Mantovani, A., Muzio, M., Ghezzi, P., Colotta, C., & Introna, M. (1998). Regulation of inhibitory pathways of the interleukin-1 system. Annals of the New York Academy of Sciences, 840, 338-351.
17. Dinarello, C. A. (2005). Blocking IL-1 in systemic inflammation. JEM, 201, 1355-1359.
18. Kawai, T., & Akira, S. (2006). TLR signaling. Cell Death and Differentiation.
19. O'Neill, L. A. (2006). How Toll-like receptors signal: what we know and what we don't know. Current Opinion in Immunology, 18, 3-9.
20. Hacham, M., Argov, S., White, R. M., Segal, S., & Apte, R. N. (2002). Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. European Cytokine Network, 13, 55-65.
21. Hacham, M., Argov, S., White, R. M., Segal, S., & Apte, R. N. (2000). Distinct patterns of IL-1 alpha and IL-1 beta organ distribution - a possible basis for organ mechanisms of innate immunity. Advances in Experimental Medicine and Biology, 479, 185-202.
22. Apte, R. N., & Voronov, E. (2002). Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Seminars in Cancer Biology, 12, 277-290.
23. Douvdevani, A., Huleihel, M., Zoller, M., Segal, S., & Apte, R. N. (1992). Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. International Journal of Cancer, 51, 822-830.
24. Zoller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992). Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response. International Journal of Cancer, 50, 450-457.
25. Zoller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992). Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection. International Journal of Cancer, 50, 443-449.
26. Apte, R. N., Douvdevani, A., Zoller, M., White, R. M., Dvorkin, T., Shimoni, N., et al. (1993). Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunology Letters, 39, 45-52.
27. Apte, R. N., Dvorkin, T., Song, X., Fima, E., Krelin, Y., Yulevitch, A., et al. (2000). Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Advances in Experimental Medicine and Biology, 479, 277-288.
28. Voronov, E., Weinstein, Y., Benharroch, D., Cagnano, E., Ofir, R., Dobkin, M., et al. (1999). Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Research, 59, 1029-1035.
29. Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., et al. (2003). Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. Journal of Immunology, 171, 6448-6456.
30. Werman, A., Werman-Venkert, R., White, R., Lee, J. K., Werman, B., Krelin, Y., et al. (2004). The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proceedings of the National Academy of Sciences of the United States of America, 101, 2434-2439.
31. Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2005). CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1{beta}-secreting cells. Journal of Immunology, 175, 8200-8208.
32. Miller, L. S., O'Connell, R. M., Gutierrez, M. A., Pietras, E. M., Shahangian, A., Gross, C. E., et al. (2006). MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity, 24, 79-91.
33. Mizel, S. B. (1982). Interleukin 1 and T cell activation. Immunological Reviews, 63, 51-72.
34. Shibuya, K., Robinson, D., Zonin, F., Hartley, S. B., Macatonia, S. E., Somoza, C., et al. (1998). IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. Journal of Immunology, 160, 1708-1716.
35. Weaver, C. T., Hawrylowicz, C. M., & Unanue, E. R. (1988). T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 85, 8181-8185.
36. McArthur, J. G., & Raulet, D. H. (1993). CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. Journal of Experimental Medicine, 178, 1645-1653.
37. Greenbaum, L. A., Horowitz, J. B., Woods, A., Pasqualini, T., Reich, E. P., & Bottomly, K. (1988). Autocrine growth of CD4+ T cells. Differential effects of IL-1 on helper and inflammatory T cells. Journal of Immunology, 140, 1555-1560.
38. Lichtman, A. H., Chin, J., Schmidt, J. A., & Abbas, A. K. (1988). Role of interleukin 1 in the activation of T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 85, 9699-9703.
39. Von Stebut, E., Ehrchen, J. M., Belkaid, Y., Kostka, S. L., Molle, K., Knop, J., et al. (2003). Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. Journal of Experimental Medicine, 198, 191-199.
40. Filippi, C., Hugues, S., Cazareth, J., Julia, V., Glaichenhaus, N., & Ugolini, S. (2003). CD4+ T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. Journal of Experimental Medicine, 198, 201-209.
41. Eriksson, U., Kurrer, M. O., Sonderegger, I., Iezzi, G., Tafuri, A., Hunziker, L., et al. (2003). Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. Journal of Experimental Medicine, 197, 323-331.
42. Su, S. B., Silver, P. B., Grajewski, R. S., Agarwal, R. K., Tang, J., Chan, C. C., et al. (2005). Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. Journal of Immunology, 175, 6303-6310.
43. Nakata, Y., Matsuda, K., Uzawa, A., Nomura, M., Akashi, M., & Suzuki, G. (1995). Administration of recombinant human IL-1 by Staphylococcus enterotoxin B prevents tolerance induction in vivo. Journal of Immunology, 155, 4231-4235.
44. Mochizuki, D. Y., Eisenman, J. R., Conlon, P. J., Larsen, A. D., & Tushinski, R. J. (1987). Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proceedings of the National Academy of Sciences of the United States of America, 84, 5267-5271.
45. Neta, R., Douches, S., & Oppenheim, J. J. (1986). Interleukin 1 is a radioprotector. Journal of Immunology, 136, 2483-2485.
46. Buryskova, M., Pospisek, M., Grothey, A., Simmet, T., & Burysek, L. (2004). Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. Journal of Biological Chemistry, 279, 4017-4026.
47. Wessendorf, J. H., Garfinkel, S., Zhan, X., Brown, S., & Maciag, T. (1993). Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. Journal of Biological Chemistry, 268, 22100-22104.
48. Maier, J. A., Statuto, M., & Ragnotti, G. (1994). Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Molecular and Cellular Biology, 14, 1845-1851.
49. Maier, J. A., Voulalas, P., Roeder, D., & Maciag, T. (1990). Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science, 249, 1570-1574.
50. Cozzolino, F., Torcia, M., Aldinucci, D., Ziche, M., Almerigogna, F., Bani, D., et al. (1990). Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proceedings of the National Academy of Sciences of the United States of America, 87, 6487-6491.
51. Garfinkel, S., Haines, D. S., Brown, S., Wessendorf, J., Gillespie, D. H., & Maciag, T. (1992). Interleukin-1 alpha mediates an alternative pathway for the antiproliferative action of poly(I.C) on human endothelial cells. Journal of Biological Chemistry, 267, 24375-24378.
52. Kumar, S., Millis, A. J., & Baglioni, C. (1992). Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 89, 4683-4687.
53. Beasley, D., & Cooper, A. L. (1999). Constitutive expression of interleukin-1alpha precursor promotes human vascular smooth muscle cell proliferation. American Journal of Physiology, 276, H901-H912.
54. Kupper, T. S., Chua, A. O., Flood, P., McGuire, J., & Gubler, U. (1987). Interleukin 1 gene expression in cultured human keratinocytes is augmented by ultraviolet irradiation. Journal of Clinical Investigation, 80, 430-436.
55. Sauder, D. N., Stanulis-Praeger, B. M., & Gilchrest, B. A. (1988). Autocrine growth stimulation of human keratinocytes by epidermal cell-derived thymocyte-activating factor: implications for skin aging. Archives of Dermatological Research, 280, 71-76.
56. Burysek, L., & Houstek, J. (1996). Multifactorial induction of gene expression and nuclear localization of mouse interleukin 1 alpha. Cytokine, 8, 460-467.
57. Douvdevani, A., Huleihel, M., Segal, S., & Apte, R. N. (1991). Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: constitutive interleukin-1 alpha transcription and manifestation of biological activity. European Cytokine Network, 2, 257-264.
58. Dvorkin, T., Song, X., Argov, S., White, R. M., Zoller, M., Segal, S., et al. (2006). Immune phenomena that are involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1a. Journal of Leukocyte Biology, 80, 96-106.
59. Apte, R. N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., et al. (2006). Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. European Journal of Cancer, 42, 751-759.
60. Dumitriu, I. E., Baruah, P., Valentinis, B., Voll, R. E., Herrmann, M., Nawroth, P. P., et al. (2005). Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. Journal of Immunology, 174, 7506-7515.
61. Lotze, M. T., & Tracey, K. J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews, Immunology, 5, 331-342.
62. Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., et al. (1998). Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. Journal of Experimental Medicine, 187, 1463-1475.
63. Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., et al. (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. Journal of Experimental Medicine, 191, 313-320.
64. Iwakura, Y. (2002). Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine & Growth Factor Reviews, 13, 341-355.
65. Nicklin, M. J., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000). Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. Journal of Experimental Medicine, 191, 303-312.
66. Nakae, S., Asano, M., Horai, R., & Iwakura, Y. (2001). Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production. Immunology, 104, 402-409.
67. Nakae, S., Asano, M., Horai, R., Sakaguchi, N., & Iwakura, Y. (2001). IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. Journal of Immunology, 167, 90-97.
68. Nakae, S., Naruse-Nakajima, C., Sudo, K., Horai, R., Asano, M., & Iwakura, Y. (2001). IL-1 alpha, but not IL-1 beta, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. International Immunology, 13, 1471-1478.
69. Voronov, E., Dayan, M., Zinger, H., Gayvoronsky, L., Lin, J-P., Iwakura, Y., et al. (2006). IL-1beta deficient mice are resistant to induction of experimental SLE. European Cytokine Network, 17, 109-116.
70. Lee, W. Y., Fischer, S. M., Butler, A. P., & Locniskar, M. F. (1993). Modulation of interleukin-1 alpha mRNA expression in mouse epidermis by tumor promoters and antagonists. Molecular Carcinogenesis, 7, 26-35.
71. Oberyszyn, T. M., Sabourin, C. L., Bijur, G. N., Oberyszyn, A. S., Boros, L. G., & Robertson, F. M. (1993). Interleukin-1 alpha gene expression and localization of interleukin-1 alpha protein during tumor promotion. Molecular Carcinogenesis, 7, 238-248.
72. La, E., Muga, S. J., Locniskar, M. F., & Fischer, S. M. (1999). Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis. Molecular Carcinogenesis, 24, 276-286.
73. Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., Marshall, J. F., et al. (2004). TNF-alpha regulates epithelial expression of MMP-9 and integrin alphav-beta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene, 23, 6954-6966.
74. Scott, K. A., Moore, R. J., Arnott, C. H., East, N., Thompson, R. G., Scallon, B. J., et al. (2003). An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther, 2, 445-451.
75. Arnott, C. H., Scott, K. A., Moore, R. J., Hewer, A., Phillips, D. H., Parker, P., et al. (2002). Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene, 21, 4728-4738.
76. Suganuma, M., Okabe, S., Marino, M. W., Sakai, A., Sueoka, E., & Fujiki, H. (1999). Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Research, 59, 4516-4518.
77. Balkwill, F. (2002). Tumor necrosis factor or tumor promoting factor? Cytokine & Growth Factor Reviews, 13, 135-141.
78. Szlosarek, P. W., & Balkwill, F. R. (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncology, 4, 565-573.
79. Knight, B., Yeoh, G. C., Husk, K. L., Ly, T., Abraham, L. J., Yu, C., et al. (2000). Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. Journal of Experimental Medicine, 192, 1809-1818.
80. Li, X., Eckard, J., Shah, R., Malluck, C., & Frenkel, K. (2002). Interleukin-1alpha up-regulation in vivo by a potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and control of DMBA-induced inflammatory responses. Cancer Research, 62, 417-423.
81. Qin, Z., Kim, H. J., Hemme, J., & Blankenstein, T. (2002). Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. Journal of Experimental Medicine, 195, 1479-1490.
82. Blankenstein, T., & Qin, Z. (2003). Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Advances in Cancer Research, 90, 179-207.
83. Blankenstein, T., & Qin, Z. (2003). The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Current Opinion in Immunology, 15, 148-154.
84. Murphy, J. E., Morales, R. E., Scott, J., & Kupper, T. S. (2003). IL-1 alpha, innate immunity, and skin carcinogenesis: The effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. Journal of Immunology, 170, 5697-5703.
85. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
86. Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
87. Lin, A., & Karin, M. (2003). NF-kappaB in cancer: a marked target. Seminars in Cancer Biology, 13, 107-114.
88. Amit, S., & Ben-Neriah, Y. (2003). NF-kappaB activation in cancer: a challenge for ubiquitination - and proteasome-based therapeutic approach. Seminars in Cancer Bioliology, 13, 15-28.
89. Stevenson, F. T., Turck, J., Locksley, R. M., & Lovett, D. H. (1997). The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proceedings of the National Academy of Sciences of the United States of America, 94, 508-513.
90. Pollock, A. S., Turck, J., & Lovett, D. H. (2003). The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB Journal, 17, 203-213.
91. Silver, A., Boultwood, J., Breckon, G., Masson, W., Adam, J., Shaw, A. R., et al. (1989). Interleukin-1 beta gene deregulation associated with chromosomal rearrangement: a candidate initiating event for murine radiation-myeloid leukemogenesis? Molecular Carcinogenesis, 2, 226-232.
92. Vanhamme, L., Marshall, G. M., Schuh, A. C., Breitman, M. L., & Vogt, P. K. (1993). Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells. Cancer Research, 53, 615-621.
93. Vale, T., Ngo, T. T., White, M. A., & Lipsky, P. E. (2001). Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Research, 61, 602-607.
94. Beaupre, D. M., Talpaz, M., Marini, F. C., 3rd, Cristiano, R. J., Roth, J. A., Estrov, Z., et al. (1999). Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Research, 59, 2971-2980.
95. Castelli, C., Sensi, M., Lupetti, R., Mortarini, R., Panceri, P., Anichini, A., et al. (1994). Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Research, 54, 4785-4790.
96. Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315, 1650-1659.
97. Radisky, D., Hagios, C., & Bissell, M. J. (2001). Tumors are unique organs defined by abnormal signaling and context. Seminars in Cancer Biology, 11, 87-95.
98. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121, 335-348.
99. Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 123, 1001-1011.
100. Stetler-Stevenson, W. G., & Yu, A. E. (2001). Proteases in invasion: matrix metalloproteinases. Seminars in Cancer Biology, 11, 143-152.
101. Strieter, R. M., Polverini, P. J., Arenberg, D. A., Walz, A., Opdenakker, G., Van Damme, J., et al. (1995). Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. Journal of Leukocyte Biology, 57, 752-762.
102. Mantovani, A., & Dejana, E. (1989). Cytokines as communication signals between leukocytes and endothelial cells. Immunology Today, 10, 370-375.
103. Folkman, J., & D'Amore, P. A. (1996). Blood vessel formation: What is its molecular basis? Cell, 87, 1153-1155.
104. Vidal-Vanaclocha, F., Amezaga, C., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994). Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Research, 54, 2667-2672.
105. Vidal-Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996). Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. Journal of the National Cancer Institute, 88, 198-205.
106. Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A. M., Anasagasti, M. J., Martin, J., et al. (2000). IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 734-739.
107. Bertomeu, M. C., Gallo, S., Lauri, D., Haas, T. A., Orr, F. W., Bastida, E., et al. (1993). Interleukin 1-induced cancer cell/endothelial cell adhesion in vitro and its relationship to metastasis in vivo: role of vessel wall 13-HODE synthesis and integrin expression. Clinical & Experimental Metastasis, 11, 243-250.
108. Carrascal, M. T., Mendoza, L., Valcarcel, M., Salado, C., Egilegor, E., Telleria, N., et al. (2003). Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Research, 63, 491-497.
109. Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 2645-2650.
110. Scherbarth, S., & Orr, F. W. (1997). Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Research, 57, 4105-4110.
111. McKenzie, R. C., Oran, A., Dinarello, C. A., & Sauder, D. N. (1996). Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Research, 16, 437-441.
112. Chirivi, R. G., Garofalo, A., Padura, I. M., Mantovani, A., & Giavazzi, R. (1993). Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Research, 53, 5051-5054.
113. Anasagasti, M. J., Olaso, E., Calvo, F., Mendoza, L., Martin, J. J., Bidaurrazaga, J., et al. (1997). Interleukin 1-dependent and - independent mouse melanoma metastases. Journal of the National Cancer Institute, 89, 645-651.
114. Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S., Kimura, Y. N., Hamano, S., et al. (2005). Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. Journal of Clinical Investigation, 115, 2979-2991.
115. Mantovani, A., Allavena, P., & Sica, A. (2004). Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. European Journal of Cancer, 40, 1660-1667.
116. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., Neckers, L. (2003). IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB Journal, 17, 2115-2117.
117. Bar, D., Apte, R. N., Voronov, E., Dinarello, C. A., & Cohen, S. (2004). A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB Journal, 18, 161-163.
118. Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., et al. (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clinical Cancer Research, 12, 1088-1096.
119. Weinreich, D. M., Elaraj, D. M., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., et al. (2003). Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Research, 63, 5957-5961.
120. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3, 991-998.
121. Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & Growth Factor Reviews, 13, 95-109.
122. Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137-148.
123. Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual Review of Immunology, 22, 329-360.
124. Estrov, Z., Kurzrock, R., Estey, E., Wetzler, M., Ferrajoli, A., Harris, D., et al. (1992). Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood, 79, 1938-1945.
125. Estrov, Z., Black, R. A., Sleath, P. R., Harris, D., Van, Q., LaPushin, R., et al. (1995). Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood, 86, 4594-4602.
126. Rambaldi, A., Torcia, M., Dinarello, C. A., Barbui, T., & Cozzolino, F. (1993). Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. Leukemia, 7(Suppl 2), S10-S12.
127. Schiro, R., Longoni, D., Rossi, V., Maglia, O., Doni, A., Arsura, M., et al. (1994). Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood, 83, 460-465.
128. Stosic-Grujicic, S., Basara, N., Milenkovic, P., & Dinarello, C. A. (1995). Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). Journal of Chemotherapy, 7, 67-70.
129. Stosic-Grujicic, S., Basara, N., & Dinarello, C. A. (1999). Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 beta converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth. Clinical and Laboratory Haematology, 21, 173-185.
130. Wetzler, M., Kurzrock, R., Estrov, Z., Kantarjian, H., Gisslinger, H., Underbrink, M. P., et al. (1994). Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood, 84, 3142-3147.
131. Lazar-Molnar, E., Hegyesi, H., Toth, S., & Falus, A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12, 547-554.
132. Nozaki, S., Sledge, G. W., Jr., & Nakshatri, H. (2000). Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochemical and Biophysical Research Communications, 275, 60-62.
133. Hayashi, H., Shimizu, R., Fujii, K., Itoh, S., Yang, D., & Onozaki, K. (1997). Resistance to IL-1 anti-proliferative effect, accompanied by characteristics of advanced melanoma, permits invasion of human melanoma cells in vitro, but not metastasis in the nude mouse. International Journal of Cancer, 71, 416-421.
134. Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., et al. (2000). Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. International Journal of Cancer, 85, 182-188.
135. Hoosein, N. M. (1998). Neuroendocrine and immune mediators in prostate cancer progression. Front Bioscience, 3, D1274-D1279.
136. Culig, Z., Hobisch, A., Herold, M., Hittmair, A., Thurnher, M., Eder, I. E., et al. (1998). Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. British Journal of Cancer, 78, 1004-1011.
137. Chiao, J. W., Hsieh, T. C., Xu, W., Sklarew, R. J., & Kancherla, R. (1999). Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1. International Journal of Oncology, 15, 1033-1037.
138. Jin, L., Yuan, R. Q., Fuchs, A., Yao, Y., Joseph, A., Schwall, R., et al. (1997). Expression of interleukin-1beta in human breast carcinoma. Cancer, 80, 421-434.
139. Miller, L. J., Kurtzman, S. H., Anderson, K., Wang, Y., Stankus, M., Renna, M., et al. (2000). Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Investigation, 18, 293-302.
140. Pantschenko, A. G., Pushkar, I., Anderson, K. H., Wang, Y., Miller, L. J., Kurtzman, S. H., et al. (2003). The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. International Journal of Oncology, 23, 269-284.
141. Palmieri, C., Roberts-Clark, D., Assadi-Sabet, A., Coope, R. C., O'Hare, M., Sunters, A., et al. (2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells. Journal of Endocrinology, 177, 65-81.
142. Tomimatsu, S., Ichikura, T., & Mochizuki, H. (2001). Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer, 91, 1272-1276.
143. Iizuka, N., Hazama, S., Hirose, K., Abe, T., Tokuda, N., Fukumoto, T., et al. (1999). Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Letter, 142, 179-184.
144. Zambon, C. F., Basso, D., Navaglia, F., Belluco, C., Falda, A., Fogar, P., et al. (2005). Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine, 29, 141-152.
145. Sehouli, J., Mustea, A., Konsgen, D., Katsares, I., & Lichtenegger, W. (2002). Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Research, 22, 3421-3424.
146. Ilyin, S. E., Gonzalez-Gomez, I., Romanovicht, A., Gayle, D., Gilles, F. H., & Plata-Salaman, C. R. (2000). Autoregulation of the interleukin-1 system and cytokine-cytokine interactions in primary human astrocytoma cells. Brain Research Bulletin, 51, 29-34.
147. Oelmann, E., Kraemer, A., Serve, H., Reufi, B., Oberberg, D., Patt, S., et al. (1997). Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. International Journal of Cancer, 71, 1066-1076.
148. Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996). CD28/B7 system of T cell costimulation. Annual Review of Immunology, 14, 233-258.
149. Chambers, C. A., & Allison, J. P. (1999). Costimulatory regulation of T cell function. Current Opinion in Cell Biology, 11, 203-210.
150. Kalli, K., Huntoon, C., Bell, M., & McKean, D. J. (1998). Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Molecular and Cellular Biology, 18, 3140-3148.
151. el-Shami, K. M., Tzehoval, E., Vadai, E., Feldman, M., & Eisenbach, L. (1999). Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. Journal of Interferon & Cytokine Research, 19, 1391-1401.
152. Marr, R. A., Addison, C. L., Snider, D., Muller, W. J., Gauldie, J., & Graham, F. L. (1997). Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Therapy, 4, 1181-1188.
153. Soo Hoo, W., Lundeen, K. A., Kohrumel, J. R., Pham, N. L., Brostoff, S. W., Bartholomew, R. M., et al. (1999). Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. Journal of Immunology, 162, 7343-7349.
154. Thompson, R. C., Pardoll, D. M., Jaffee, E. M., Ewend, M. G., Thomas, M. C., Tyler, B. M., et al. (1996). Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. Journal of Immunotherapy with Emphasis on Tumor Immunology, 19, 405-413.
155. Chirivi, R. G., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., et al. (1996). IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. International Journal of Cancer, 67, 856-863.
156. Esandi, M. C., van Someren, G. D., Bout, A., Mulder, A. H., van Bekkum, D. W., Valerio, D., et al. (1998). IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells. Gene Therapy, 5, 778-788.
157. Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology, 176, 284-290.
158. Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., et al. (2002). Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. Journal of Immunology, 169, 469-475.
159. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews, Immunology, 4, 941-952.
160. Kusmartsev, S., & Gabrilovich, D. I. (2002). Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology and Immunotherapy, 51, 293-298.
161. Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., et al. (2004). Derangement of immune responses by myeloid suppressor cells. Cancer Immunology and Immunotherapy, 53, 64-72.
162. Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6, 409-421.
163. Okazaki, T., Ebihara, S., Asada, M., Kanda, A., Sasaki, H., & Yamaya, M. (2006). Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. International Immunology, 18, 1-9.
164. Ruiz de Almodovar, C., Luttun, A., & Carmeliet, P. (2006). An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell, 124, 18-21.
165. Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., et al. (2006). VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell, 124, 175-189.